Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20090435 | 0.83 | CYP2C19 (0.40) | CYP2C9 | |
| SCHEMBL417796 | 0.78 | CYP3A4 (0.46) | SNCACYP2C9MET | |
| SCHEMBL411738 | 0.77 | CYP1A2 (0.47) | CYP2C9MET | |
| SCHEMBL412863 | 0.73 | MET (0.58) | MET | |
| SCHEMBL410294 | 0.73 | KIT (0.45) | MET | |
| SCHEMBL7963485 | 0.68 | FGFR1 (0.47) | MET | |
| SCHEMBL410185 | 0.67 | GPR84 (0.50) | MET | |
| SCHEMBL858767 | 0.65 | CYP2C9 (0.49) | SNCACYP2C9 | |
| SCHEMBL415646 | 0.65 | PLK4 (0.41) | SNCAIGF1RCYP2C9MET | |
| SCHEMBL856403 | 0.65 | CYP3A4 (0.38) | IGF1RCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRD4 727/4885SNCA 3604/4885IGF1R 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.